Management algorithm for subclinical hypoxemia in coronavirus disease-2019 patients: Intercepting the 'Silent Killer'

12Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.
Get full text

Abstract

In the early stages of COVID-19 clinical illness, the ability to oxygenate is impaired. However, the patient does not necessarily display the conventionally expected signs or symptoms of respiratory failure, including shortness of breath. Given the above, HCP's must remain vigilant and proactively look for 'red flags' described herein, such as the appearance of =3%-5% drop in SpO2 after approximately 60 s of mild activity/ambulation, SpO2/FiO2 ratio <300, SpO2 <93% on room air, and the presence of hypoxemia without tachypnea [Figure 1].[4,11,12] In summary, this expert group views AH as the proverbial "canary in the coalmine" and the first harbinger of future respiratory deterioration in COVID-19 patients.

Cite

CITATION STYLE

APA

Galwankar, S., Paladino, L., Gaieski, D., Nanayakkara, K., Somma, S., Grover, J., & Stawicki, S. (2020, April 1). Management algorithm for subclinical hypoxemia in coronavirus disease-2019 patients: Intercepting the “Silent Killer.” Journal of Emergencies, Trauma and Shock. Wolters Kluwer Medknow Publications. https://doi.org/10.4103/JETS.JETS_72_20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free